Treating Chronic Pain with SSRIs: What Do We Know?

Serotonin is a monoamine neurotransmitter that plays a major role in both nociception and mood regulation. Alterations in the 5-hydroxytryptophan (5HT) system have been reported in chronic pain patients. In recent years, Selective Serotonin Reuptake Inhibitors (SSRIs) have been suggested as an alter...

Full description

Bibliographic Details
Main Authors: Elias Patetsos, Emilia Horjales-Araujo
Format: Article
Language:English
Published: Hindawi Limited 2016-01-01
Series:Pain Research and Management
Online Access:http://dx.doi.org/10.1155/2016/2020915
id doaj-869c2237742342f6bb6bce68d1876ac6
record_format Article
spelling doaj-869c2237742342f6bb6bce68d1876ac62020-11-25T00:31:12ZengHindawi LimitedPain Research and Management1203-67651918-15232016-01-01201610.1155/2016/20209152020915Treating Chronic Pain with SSRIs: What Do We Know?Elias Patetsos0Emilia Horjales-Araujo1Copenhagen University, 2200 Copenhagen, DenmarkDepartment of Anesthesia, Center of Head and Orthopedics, Copenhagen University Hospital, 2200 Copenhagen, DenmarkSerotonin is a monoamine neurotransmitter that plays a major role in both nociception and mood regulation. Alterations in the 5-hydroxytryptophan (5HT) system have been reported in chronic pain patients. In recent years, Selective Serotonin Reuptake Inhibitors (SSRIs) have been suggested as an alternative treatment for chronic pain due to the fact that they are better tolerated presenting less secondary effects than other antidepressants such as tricyclic antidepressants. Although several clinical trials have been published, the effectiveness of SSRI as treatment for pain conditions is inconclusive. This review aims to summarise what is known, regarding the effectiveness of SSRI as a treatment for chronic pain conditions in adults. A total of 36 studies involving a total of 1898 participants were included in this review. Of the 36 trials included in the review, 2 used zimelidine as treatment, 3 used escitalopram, 4 used fluvoxamine, 4 used sertraline, 6 used citalopram, 8 used paroxetine, 9 used fluoxetine, and one used both citalopram and paroxetine. Because the trials included in this review are quite heterogeneous, only qualitative analyses were performed. SSRI seems to have an effect on most of chronic pain conditions; however, further clinical trials with good methodology leading to low risk of bias are needed in order to conclude once and for all the effect of this drug class as treatment for chronic pain conditions.http://dx.doi.org/10.1155/2016/2020915
collection DOAJ
language English
format Article
sources DOAJ
author Elias Patetsos
Emilia Horjales-Araujo
spellingShingle Elias Patetsos
Emilia Horjales-Araujo
Treating Chronic Pain with SSRIs: What Do We Know?
Pain Research and Management
author_facet Elias Patetsos
Emilia Horjales-Araujo
author_sort Elias Patetsos
title Treating Chronic Pain with SSRIs: What Do We Know?
title_short Treating Chronic Pain with SSRIs: What Do We Know?
title_full Treating Chronic Pain with SSRIs: What Do We Know?
title_fullStr Treating Chronic Pain with SSRIs: What Do We Know?
title_full_unstemmed Treating Chronic Pain with SSRIs: What Do We Know?
title_sort treating chronic pain with ssris: what do we know?
publisher Hindawi Limited
series Pain Research and Management
issn 1203-6765
1918-1523
publishDate 2016-01-01
description Serotonin is a monoamine neurotransmitter that plays a major role in both nociception and mood regulation. Alterations in the 5-hydroxytryptophan (5HT) system have been reported in chronic pain patients. In recent years, Selective Serotonin Reuptake Inhibitors (SSRIs) have been suggested as an alternative treatment for chronic pain due to the fact that they are better tolerated presenting less secondary effects than other antidepressants such as tricyclic antidepressants. Although several clinical trials have been published, the effectiveness of SSRI as treatment for pain conditions is inconclusive. This review aims to summarise what is known, regarding the effectiveness of SSRI as a treatment for chronic pain conditions in adults. A total of 36 studies involving a total of 1898 participants were included in this review. Of the 36 trials included in the review, 2 used zimelidine as treatment, 3 used escitalopram, 4 used fluvoxamine, 4 used sertraline, 6 used citalopram, 8 used paroxetine, 9 used fluoxetine, and one used both citalopram and paroxetine. Because the trials included in this review are quite heterogeneous, only qualitative analyses were performed. SSRI seems to have an effect on most of chronic pain conditions; however, further clinical trials with good methodology leading to low risk of bias are needed in order to conclude once and for all the effect of this drug class as treatment for chronic pain conditions.
url http://dx.doi.org/10.1155/2016/2020915
work_keys_str_mv AT eliaspatetsos treatingchronicpainwithssriswhatdoweknow
AT emiliahorjalesaraujo treatingchronicpainwithssriswhatdoweknow
_version_ 1725323125118205952